Adesto Technologies (IOTS) At $6.60 Forms Top; Biotime (BTX) Sentiment Is 1.96

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $331.12 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.07 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Adesto Technologies Corporation (IOTS) formed multiple top with $6.86 target or 4.00% above today’s $6.60 share price. Adesto Technologies Corporation (IOTS) has $139.52 million valuation. The stock increased 2.33% or $0.15 during the last trading session, reaching $6.6. About 51,951 shares traded. Adesto Technologies Corporation (NASDAQ:IOTS) has risen 50.86% since February 13, 2017 and is uptrending. It has outperformed by 34.16% the S&P500.

The stock increased 1.16% or $0.03 during the last trading session, reaching $2.61. About 393,181 shares traded. BioTime, Inc. (BTX) has risen 22.71% since February 13, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

Broadwood Capital Inc holds 12.83% of its portfolio in BioTime, Inc. for 27.28 million shares. Manatuck Hill Partners Llc owns 351,822 shares or 0.49% of their US portfolio. Moreover, Family Management Corp has 0.35% invested in the company for 182,350 shares. The Florida-based Prescott General Partners Llc has invested 0.27% in the stock. Carl Domino Inc, a Florida-based fund reported 37,000 shares.

Since January 1, 0001, it had 1 insider purchase, and 0 sales for $7.00 million activity.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: